New cocktail attack on stubborn colon cancer

NCT ID NCT07622550

Not yet recruiting Disease control Sponsor: Jiangsu Cancer Institute & Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two targeted drugs (fruquintinib and serplulimab) plus chemotherapy as a first treatment for 80 people with advanced colorectal cancer that has RAS or BRAF mutations. The goal is to see if this mix can delay cancer growth and improve survival. Participants will receive the drugs in cycles, followed by maintenance therapy if their disease is controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib, serplulimab, and chemotherapy (oxaliplatin and capecitabine)
What this could lead to: If successful, this could offer a new first-line treatment option for people with a hard-to-treat form of advanced colorectal cancer.
What could go wrong: This is a small, early-phase (phase 2) trial with no control group, so results may not be definitive. The drug combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Changshu No.2 People's Hospital

Suzhou, Jiangsu, 215000, China
Changzhou Tumor Hospital (Changzhou Fourth People's Hospital)

Changzhou, Jiangsu, 213000, China
First Affiliated Hospital of Nanjing Medical Unviersity

Nanjing, Jiangsu, 210000, China
Huaian First People's Hospital

Huai'an, Jiangsu, 223000, China
Jiangsu Cancer Institute & Hospital

Nanjing, Jiangsu, 210000, China
Jiangyin People's Hospital

Wuxi, Jiangsu, 214400, China
Liyang People's Hospital

Changzhou, Jiangsu, 213000, China
Nantong University Cancer Hospital

Nantong, Jiangsu, 226000, China
Suzhou Municipal Hospital

Suzhou, Jiangsu, 215000, China
The First People's Hospital of Changzhou

Changzhou, Jiangsu, 213000, China
The First People's Hospital of Lianyungang

Lianyungang, Jiangsu, 222000, China
The First People's Hospital of Nantong

Nantong, Jiangsu, 226000, China
Wuxi Huishan District People's Hospital

Wuxi, Jiangsu, 214000, China
Xuzhou First People's Hospital

Xuzhou, Jiangsu, 221000, China
Yangzhou University Affiliated Jiangdu People's Hospital

Yangzhou, Jiangsu, 225000, China
Yizheng People's Hospital

Yangzhou, Jiangsu, 225000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.